Bristol-Myers Squibb Company (BMY) to Capitalize on Cell Therapy Edge to Pursue CAR-T Treatment Opportunities

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best conservative stocks to buy now. On September 23, at the Bernstein Insights: Healthcare Leaders and Disruptors, the company emphasized its leadership in cell therapy.

Bristol-Myers Squibb Company (BMY) to Capitalize on Cell Therapy Edge to Pursue CAR-T Treatment Opportunities

The remarks come on the company treating 13,000 patients with cell therapy while leveraging extensive clinical data.

“As we sit four years later, after treating 13,000 patients, we sit in a unique position at Bristol Myers Squibb where we have more manufactured clinical and translational data than almost anyone else in this space. It has afforded us the opportunity not only to grow our inline assets, but it’s helped us accelerate our pipeline,” said Lynelle, Head of the Cell Therapy business, Bristol Myers Squibb.

Approved to treat certain adult lymphomas, Breyanzi is the company’s lead cell-based gene therapy. With only 20% of eligible patents currently receiving CAR T therapy, the company is staring at tremendous opportunities.

Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and sells innovative medicines to treat serious diseases, with a focus on areas like oncology, immunology, hematology, and cardiovascular disease.

While we acknowledge the potential of Bristol-Myers Squibb Company (NYSE:BMY) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BMY and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Best Performing Penny Stocks to Buy Now and 11 Best Healthcare Penny Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.